AIM Vaccine Co., Ltd.
HKSE: 6660.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yan Zhou
- Employees
- 1,535
- Headquarters
- Beijing, China
- IPO year
- 2022
- Market cap
- HK$3.8B
- Website
- https://www.aimbio.com
Loading 6660…
Loading profile data…Frequently asked questions about 6660
What does AIM Vaccine Co., Ltd. (6660.HK) do?
AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV...
Where does 6660.HK trade?
AIM Vaccine Co., Ltd. (6660.HK) trades on the Hong Kong Stock Exchange.
What sector is 6660.HK in?
AIM Vaccine Co., Ltd. (6660.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AIM Vaccine Co., Ltd.?
Yan Zhou is the chief executive officer of AIM Vaccine Co., Ltd. (6660.HK).
Where is AIM Vaccine Co., Ltd. headquartered?
AIM Vaccine Co., Ltd. is headquartered in China.
Does 6660.HK pay a dividend?
AIM Vaccine Co., Ltd. (6660.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6660.HK go public?
AIM Vaccine Co., Ltd. (6660.HK) completed its initial public offering in 2022.